The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

While the year started out as cautiously optimistic, stemming from the peak of biotech initial public offering (IPO) activity ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable muscle-invasive bladder cancer (MIBC).

The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal’s Zegfrovy (sunvozertinib) to treat a ...

Early commercialisation is one of the most demanding stages in bringing a therapy to market, and the challenges are only ...

Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

A WHO report emphasises the serious global impact of antimicrobial resistance, which exacerbates the substantial burden of ...

“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...

The European Commission (EC) has granted conditional approval to Jazz Pharmaceuticals’ Ziihera (zanidatamab) to treat a ...

Camera fatigue: being on camera means always being on show. This can be distracting for some individuals who are constantly ...